Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Sanofi Winthrop Industrie
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
May 23, 2026
Press Release: Sanofi’s Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
May 22, 2026
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
May 22, 2026
Press Release: ESCMID: Sanofi’s Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study
May 22, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
May 21, 2026
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
May 20, 2026
Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease
May 19, 2026
Press Release: Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma
May 19, 2026
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid
May 19, 2026
Press release: Availability of the Q1 2026 aide-mémoire
May 19, 2026
←
Previous Page
1
2
3
Next Page
→